DNA science background
← ECO·GRAIL
Powered by GRAIL

Screen for 50+
cancers with a
single blood test.

The Galleri® multi-cancer early detection test — now available exclusively through Human Longevity. Detect cancer signals before symptoms appear, across cancers that have no recommended screening today.

50+
Cancer types screened
99.5%
Specificity — very low false positives
20,000+
Clinical trial participants
More cancers detected vs. single-cancer screens alone
Clinical Partnership

Human Longevity is proud to offer the Galleri® test by GRAIL — the first multi-cancer early detection blood test to achieve large-scale clinical validation with over 20,000 study participants, studied at leading cancer institutions worldwide.

Galleri® is a registered trademark of GRAIL, Inc.
Detection Scope

Over 50 cancer types.
Many with no other
screening option.

Most cancers have no recommended screening tests today. Galleri® changes that — identifying a "cancer fingerprint" of methylation patterns in cell-free DNA shed by cancer cells into your bloodstream.

Lung
Colorectal
Pancreatic
Ovarian
Esophageal
Gastric
Hepatobiliary
Bladder
Head & Neck
Lymphoid
Breast
Cervical
Thyroid
Kidney
Prostate
Leukemia
Melanoma
Myeloma
Uterine
Sarcoma
+30 more cancer types
Process

From blood draw
to actionable results.

01

Order & Schedule

Request your Galleri test through Human Longevity. A physician order is placed and you schedule a convenient blood draw appointment.

02

Simple Blood Draw

A single 2-tube blood draw — no fasting, no prep. The test analyzes cell-free DNA shed by cancer cells into the bloodstream.

03

Lab Analysis

GRAIL's CLIA-certified clinical laboratory uses advanced methylation analysis to identify cancer signals and localize their tissue of origin.

04

Results & Guidance

Your HLI physician reviews your results with you. If a signal is detected, immediate next steps and diagnostic workup are coordinated.

Patient receiving test results
Clinical Evidence

Validated across
20,000+ participants.

The PATHFINDER and PATHFINDER 2 studies demonstrated that adding the Galleri test to standard recommended screenings approximately doubled the number of cancers detected — most in early, more treatable stages.

~2×
More cancers detected when added to standard screening
75%
Of signals, when detected, localized to tissue of origin

Studied at

Memorial Sloan Kettering · Dana-Farber · Cleveland Clinic · Mayo Clinic · Johns Hopkins · Intermountain Health · and 14 other leading cancer centers

Real-World Evidence

Over 100,000 tests.
Peer-reviewed results.

A 2025 study published in Nature Communications analyzed real-world data from more than 100,000 multi-cancer early detection tests — the largest clinical experience reported to date. Across a median participant age of 58, the test detected invasive cancers spanning 32 distinct cancer types, many of which have no recommended screening available today.

111,080
Individuals evaluated (median age 58)
87%
Cancer signal origin correctly predicted, in cases with a reported cancer type
39.5 days
Median time from result to cancer diagnosis
74%
Of detected cancers had no recommended screening test available
~0.91%
Of tests returned a cancer signal detected result
~99.5%
Specificity — approximately 0.5% false positive rate
Source

Matrana M, Shukla V, Kingsbury D, et al. Real-world data and clinical experience from over 100,000 multi-cancer early detection tests. Nature Communications 16, 9625 (2025). doi.org/10.1038/s41467-025-64094-7 ↗

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. Galleri is not recommended for individuals who are pregnant, age 21 or younger, or undergoing active cancer treatment. Galleri does not detect all cancers and should not replace routine cancer screenings recommended by your healthcare provider. Results should be interpreted by a healthcare provider in the context of medical history. A test result of No Cancer Signal Detected does not rule out cancer. False positive and false negative results do occur. Rx only.

Couple walking
Get Started

Take control
of your cancer risk.

One blood draw. Over 50 cancers. Every order includes a full year of complimentary access to HLI's AI precision medicine app — turning your results into a longitudinal plan for your health.

$1,200 List Price
$798Exclusive Member Price — Limited‑Time Offer
HSA/FSA eligible · One-time charge
Includes 1 year of complimentary access to HLI's AI precision medicine app
← Back to all ECO services

A physician consultation is required. Human Longevity physicians will review eligibility and issue an order. Available to patients 50+ or those at elevated cancer risk.